An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.
Ning LiHualei BuJihong LiuJian Qing ZhuQi ZhouLi WangRutie YinXiaohua WuShuzhong YaoKangsheng GuHui ZhangHongming PanQiang WuRuifang AnXinfeng YangXiaoping WanWei DuanJianping XiongHongyan GuoGe LouJing WangWenjing HuXin ZhangYuanguang MengBen ZhangYuting WangQuanren WangLingying WuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Fluzoparib demonstrated promising antitumor activity and acceptable safety profile in germline BRCA1/2-mutated, platinum-sensitive relapsed ovarian cancer. Thus, fluzoparib might be a novel treatment option for this population.